Page 6,814«..1020..6,8136,8146,8156,816..6,8206,830..»

One Piece Episode 550 Review – The Evil Drug's True Power – Video

Posted: Published on June 4th, 2012

03-06-2012 12:33 My review of One Piece Episode 550 😀 This episode we find out the side-effects of taking the Energy Steroid the new fishman pirates are constantly taking to get more power Read this article: One Piece Episode 550 Review - The Evil Drug's True Power - Video … Continue reading

Posted in Drug Side Effects | Comments Off on One Piece Episode 550 Review – The Evil Drug's True Power – Video

Older Drug for Advanced Breast Cancer Beat Newer, Pricier Meds

Posted: Published on June 4th, 2012

A woman doing a self-check for breast cancer. By E.J. Mundell HealthDay Reporter MONDAY, June 4 (HealthDay News) -- Even in the field of cancer treatment, sometimes newer isn't necessarily better. That may be the case for patients with advanced breast cancer, who appeared to fare better in a new study when they took an older drug, Taxol (paclitaxel), instead of two newer and more expensive rivals. Both of those newer medications, Abraxane and Ixempra, failed to outperform Taxol in terms of either survival without progression of disease or the level of the most noxious side effects, the study of almost 800 breast cancer patients found. [Health Buzz: Worldwide Cancer Incidence Predicted to Rise.] "These data suggest that similar patients may be appropriately treated with weekly paclitaxel [Taxol]," said study author Dr. Hope Rugo, director of breast oncology and clinical trials at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. She spoke at a news briefing Sunday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The study, which was funded by the U.S. National Cancer Institute, is to be formally presented on Monday. Taxol has been used for years to … Continue reading

Posted in Drug Side Effects | Comments Off on Older Drug for Advanced Breast Cancer Beat Newer, Pricier Meds

New Legislation Proposed to Hold Generic Drug Manufacturers Responsible for Side Effects

Posted: Published on June 4th, 2012

Attorney (866) 735-1102 Ext 305 Senator Patrick Leahy has recently introduced new legislation in hopes to restore the rights of citizens and hold drug manufacturers of generic brand drugs accountable for failing to warn adequately regarding the side effects which can be associated with the generic medication. This legislation will help restore and protect citizen rights. We strongly encourage you and your family to contact your representatives in the U.S. Senate and House of Representatives to ask for them to support this new legislation. According to a recent Press Release, Senators Richard Blumenthal, Jeff Bingaman, Sheldon Whitehouse, Christopher Coons, Sherrod Brown, and Al Franken have cosponsored the legislation. The new legislation is titled the Patient Safety and Generic Labeling Improvement Act. The reason for the introduction of this legislation comes after a 2011 Supreme Court case, Pilva v. Mensing, where the Court found in a 5-4 majority opinion that generic drug manufacturers cannot be held liable under state tort law for failing to warn consumers even when the companies know the label on the drug is inadequate. This decision does not make sense when compared to a 2008 case where the Supreme Court held that manufacturers of brand name drugs … Continue reading

Posted in Drug Side Effects | Comments Off on New Legislation Proposed to Hold Generic Drug Manufacturers Responsible for Side Effects

Breakthrough as new breast cancer drug increases remission time and reduces side-effects of chemotherapy

Posted: Published on June 4th, 2012

Drug T-DM1 proven to stall the disease longer than current treatments, says NHS Trust Drug block growth of cancer, then destroys cancer cells from within Could be available for sufferers within a few years By Eddie Wrenn PUBLISHED: 10:05 EST, 4 June 2012 | UPDATED: 10:05 EST, 4 June 2012 The new treatment uses a two-stage approach to stop cancers growing - and then destroy them from within Medical experts in the UK have made a major breakthrough in their research to keep breast cancer at bay for longer. A new drug, which has been tested, has been proven to stall the disease for longer than current treatments, providing fresh hope for patients. The Freeman Hospital in Newcastle was among a handful of centres across the world to test a new treatment for advanced breast cancer. Results from the study also show the drug, T-DM1, significantly reduces the side effects of chemotherapy. While T-DM1 is undergoing further trials, the discovery is being hailed as a major step forward. Dr Mark Verrill, consultant medical oncologist at the Newcastle Hospitals NHS Foundation Trust, has played a key role in the study, which specifically looked at an advanced form of the disease known … Continue reading

Posted in Drug Side Effects | Comments Off on Breakthrough as new breast cancer drug increases remission time and reduces side-effects of chemotherapy

'Magic Bullet' Drug Delays Breast Cancer Worsening

Posted: Published on June 4th, 2012

T-DM1 Spares Women From Some, But Not All, Serious Side Effects June 4, 2012 (Chicago) -- A new targeted cancer drug delayed the worsening of metastatic breast cancer, possibly with fewer side effects than traditional treatments, according to results of a late-stage study. Called T-DM1, the new drug combines Herceptin with a potent chemotherapy drug. It's been called a "magic bullet": Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target without damaging nearby cells. The study involved nearly 1,000 women with metastatic breast cancer that was continuing to get worse despite treatment with Herceptin and a common chemotherapy drug. Half the women got T-DM1 and the other half got Tykerb and Xeloda, a standard treatment for women who aren't helped by Herceptin. T-DM1 delayed the time to the disease progressing by about three months. Among women who received T-DM1, the average time before the disease got worse was about nine-and-a-half months vs. about six-and-a-half months for those getting the standard drugs. Although a few months might not sound like much, it can be a huge gain for seriously ill patients who are running out of options, say doctors studying the drug. It is still … Continue reading

Posted in Drug Side Effects | Comments Off on 'Magic Bullet' Drug Delays Breast Cancer Worsening

New Cancer Drug Targets Tumor Cells, Reduces Side Effects

Posted: Published on June 4th, 2012

June 4, 2012 A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According to Reuters reporter Deena Beasley, the treatment combines Roches antibody Herceptin (trastuzumab) and a cell-killing compound adapted from chemotherapy drugs and developed by ImmunoGen. The result is what she refers to as an armed antibody, and what USA Todays Liz Szabo describes as a drug combination designed to act like a smart bomb, which delivers its payload directly to tumor cells while reducing collateral damage to the rest of the body. Approximately 1,000 patients suffering from advanced or metastatic breast cancer, all of whom had previously received treatment from both a taxane chemotherapy drug and Herceptin, participated in the study, Beasley said. Those who took TDM-1 lived for a median of 9.6 months before their symptoms worsened, compared to just 6.4 months for those who … Continue reading

Posted in Drug Side Effects | Comments Off on New Cancer Drug Targets Tumor Cells, Reduces Side Effects

Arizona prisons struggle with drugs

Posted: Published on June 4th, 2012

by Bob Ortega - Jun. 3, 2012 11:10 PM The Republic | azcentral.com Orion Wilkins was a drug addict, hooked on painkillers he'd begun taking to fight the pain of an old high-school football injury. In 2008, he used a wrapped block of Velveeta cheese, claiming it was a bomb, to rob several Valley pharmacies of pain pills to feed his addiction. He was convicted of armed robbery and sentenced to 101/2 years in prison. Three years later, on Dec. 7, 2011, Wilkins, 35, died of a drug overdose inside the Arizona state prison in Florence. The presence of illegal drugs inside what are supposed to be the most secure buildings in the state has led to the deaths of at least seven inmates from overdoses, all involving heroin, over the past two years. The state Department of Corrections classified the deaths as accidental. The Arizona Republic investigated these deaths as part of a broader look at the high rates of suicide, homicide and accidental deaths in Arizona's state prisons. The ability of inmates to get drugs and hypodermic needles while behind bars suggests that the Department of Corrections has its own drug problem: a porous security system that allows … Continue reading

Posted in Drugs | Comments Off on Arizona prisons struggle with drugs

Glaxo Gene-Blocking Melanoma Drugs Beat Chemotherapy in Studies

Posted: Published on June 4th, 2012

By Makiko Kitamura and Robert Langreth - 2012-06-04T04:00:01Z Two experimental GlaxoSmithKline Plc (GSK) drugs that block genes tied to lethal skin cancer worked better than chemotherapy in studies that tested them individually, paving the way for final-phase trials on their use together. About 80 percent of patients with advanced melanoma given Glaxos trametinib were alive after six months, compared with 67 percent on chemotherapy used as a standard treatment. Separately, Glaxos dabrafenib delayed disease progression by 5.1 months, compared with 2.7 months for chemotherapy. The Glaxo-funded research is being reported today at the American Society of Clinical Oncology meeting in Chicago. The individual research followed an early-stage study in 77 patients that found the drugs used together resulted in fewer skin lesions than previously reported with Roche Holding AG (ROG)s Zelboraf, a therapy cleared last year that targets a mutant gene found in half of advanced melanoma cases. Glaxo has begun two final-stage trials on the combo therapy, the company said. The combination is where we have the most enthusiasm right now, said Keith Flaherty, director for developmental cancer therapeutics at Massachusetts General Hospital in Boston, and an author on the trametinib study. It looks better in terms of efficacy, … Continue reading

Posted in Drugs | Comments Off on Glaxo Gene-Blocking Melanoma Drugs Beat Chemotherapy in Studies

Leading Anti-Cancer Drugs and Associated Market 2012-2022

Posted: Published on June 4th, 2012

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Leading Anti-Cancer Drugs and Associated Market 2012-2022 http://www.reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Cancer treatments - discover which products have greatest potential Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022. How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs. Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues: Traditional antineoplastic agents View original post here: Leading Anti-Cancer Drugs and Associated Market 2012-2022 … Continue reading

Posted in Drugs | Comments Off on Leading Anti-Cancer Drugs and Associated Market 2012-2022

World Biological Drugs Market 2012-2022

Posted: Published on June 4th, 2012

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: World Biological Drugs Market 2012-2022 http://www.reportlinker.com/p0470101/World-Biological-Drugs-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Your guide to biopharma industry trends and revenue prospects Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. Our new study investigates biotechnology in pharma - biological drugs (biopharmaceuticals, biologics). It lets you assess potential sales trends at world market, submarket, product and regional level to 2022. How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of submarkets to 2022, finding potential revenues: Monoclonal antibodies (MAbs) and fusion proteins Go here to read the rest: World Biological Drugs Market 2012-2022 … Continue reading

Posted in Drugs | Comments Off on World Biological Drugs Market 2012-2022

Page 6,814«..1020..6,8136,8146,8156,816..6,8206,830..»